• Twitter
  • RSS
InterveXion Therapeutics
  • About Us
    • Overview
    • Management Team and Founders
    • Financial Conflict of Interest
  • Research & Development
    • Anti-Methamphetamine Products
    • Intellectual Property
    • Methamphetamine Use Statistics
  • Publications
    • Recent Publications
    • Anti-Methamphetamine Monoclonal Antibody
    • METH Vaccine
    • Anti-Phencyclidine Monoclonal Antibody
    • Review Articles
  • Contact Us
  • News
Select Page

ARRA Grant Award to Fund Development of Anti-METH mAb

Oct 1, 2009 | Anti-METH ch-mAb7F9, Grants, Uncategorized

InterveXion has been awarded a two year $3.9 million grant entitled “Chimeric anti-Methamphetamine Monoclonal Antibody for Treating Stimulant Toxicity” by the National Institutes of Health, National Institute on Drug Abuse (NIDA) as part of the American Recovery and...

Recent Posts

  • InterveXion Enrolls First Patient in Phase 2 Study of the Effect of IXT-m200 on Methamphetamine PK and PD
  • InterveXion Licenses Asian Rights to Novel Anti-Methamphetamine Antibody to Ascent Therapeutics
  • InterveXion Awarded $8M to Fund Phase 2 Clinical Study of Anti-Methamphetamine Medication
  • STAMPOUT study to be conducted in METH users when funded
  • InterveXion Therapeutics Announces Fast Track Designation of IXT-m200 for Treatment of Methamphetamine Addiction

Recent Comments

    Archives

    • May 2018
    • January 2018
    • October 2017
    • June 2017
    • January 2016
    • January 2015
    • November 2014
    • February 2014
    • August 2013
    • July 2013
    • December 2012
    • November 2012
    • May 2012
    • April 2012
    • July 2011
    • April 2011
    • October 2009
    • September 2009
    • March 2005
    • January 2005

    Categories

    • Anti-METH ch-mAb7F9
    • Anti-METH Vaccine
    • Anti-PCP ch-mAb6B5
    • General News
    • Grants
    • Uncategorized

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
    • Twitter
    • RSS
    © 2017 Intervexion